🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseDe novo lipogenesis reduction on GLP-1 — mechanistic hepatology

De novo lipogenesis reduction on GLP-1 — mechanistic hepatology

MASHdoc_SA Mon, Jun 1, 2026 at 1:48 AM 17 replies 523 viewsPage 1 of 4
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Jun 1, 2026 at 1:48 AM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

The narrow version of the question is whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is. I have searched first, so if this is covered somewhere point me at it and I will read it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
8 3TirzTom, TrialTracker_MD, JennaRN and 5 others
Reply Quote Save Share Report
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Jun 1, 2026 at 2:13 AM#2
MASHdoc_SA said:
The liver data is among the strongest non-weight findings in the class.

Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 340 dB/m (moderate steatosis) and stiffness 9.8 kPa (possible fibrosis). Diagnosed with NAFLD.

After 14 months: CAP dropped to 243 dB/m (minimal steatosis) and stiffness normalized to 6.1 kPa. Hepatologist says the liver is essentially healing itself as the metabolic stress resolves.

GLP-1 agonists may become first-line NASH therapy. The Phase 3 data on semaglutide for NASH is very promising.

7 2newstart_MO, mia_MS2, LeilaHI and 4 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Jun 1, 2026 at 2:38 AM#3
MASHdoc_SA said:
The liver data is among the strongest non-weight findings in the class.

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
6 1maya_sedona, stefan_berlin, Dr.EM_Chicago and 3 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Jun 1, 2026 at 3:03 AM#4
TrialTracker_MD said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

Last edited: Jun 1, 2026 at 5:03 AM
5 0Dr.PeteFamMed, claudia_zurich, nancy_portland and 2 others
Reply Quote Save Share Report
WendyG_ATL
Member
1,023
5,678
Apr 2024
Georgia
Jun 1, 2026 at 5:18 AM#5
mike.trainer_LA said:
Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 340 dB/m (moderate steatosis) and stiffness 9.8 kPa (possible…

This is my experience too, for whatever a second data point is worth. I had assumed I was the exception until I read this.

4 24DebRD_ATL, KristenIndy, MarkLI_maint and 1 other
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register